Search
Elagolix
go.drugbank.com/drugs/DB11979ApprovedInvestigationalMoreover, women who are affected by this condition can suffer for up to six to ten years and visit multiple physicians before receiving a proper diagnosis [A35868, A35869, F801].
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitorsGadolinium
go.drugbank.com/drugs/DB12091ApprovedInvestigationalWithdrawnGadolinium is under investigation in Hypertension, ACUTE KIDNEY INJURY, and Chronic Kidney Disease. Gadolinium has been investigated for the basic science of CAD, Multiple Sclerosis, and Coronary Artery Disease.
Categories: Compounds used in a research, industrial, or household settingTelotristat ethyl
go.drugbank.com/drugs/DB12095ApprovedTelotristat ethyl is a prodrug of telotristat that was approved by the FDA in March 2017 as Xermelo. … [A252937] Serotonin is metabolized in the urinary metabolite 5-hydroxy indole acetic acid (u5-HIAA), and high levels of u5-HIAA is associated with poor survival outcome in patients with NET.
Categories: Cytochrome P-450 CYP2B6 Inducers, P-glycoprotein inhibitorsUlimorelin
go.drugbank.com/drugs/DB12128InvestigationalUlimorelin is a novel small molecule ghrelin agonist being developed by Tranzyme Pharma as a first-in-class treatment for both POI and diabetic gastroparesis, serious medical conditions in which motility
Lorlatinib
go.drugbank.com/drugs/DB12130ApprovedInvestigationalLorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer[L39905] which was first approved by the US FDA in November of 2018 … approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-positive non-small cell lung cancer, followed by an expanded approval in 2022 to include lorlatinib as a
Categories: MATE 1 Inhibitors, P-glycoprotein inducersProducts: LORBRENA® 25 MG, LORBRENA® 100 MGGepotidacin
go.drugbank.com/drugs/DB12134ApprovedInvestigational[A273755] By inhibiting two distinct bacterial enzymes, a lower potential for the development of resistance to gepotidacin is expected. … Gepotidacin is a first-in-class triazaacenaphthylene antibacterial targeting bacterial DNA gyrase and topoisomerase IV.[L52685] Its target is similar to that of fluoroquinolone antibacterials - e.g.
Categories: MATE 1 Inhibitors, MATE 2 InhibitorsGilteritinib
go.drugbank.com/drugs/DB12141ApprovedInvestigational[A40036] It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression observed in other therapies. … Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group.
Categories: MATE 1 Inhibitors, Cytochrome P-450 SubstratesProducts: XOSPATA® FILM-COATED TABLETS 40MGGepirone
go.drugbank.com/drugs/DB12184ApprovedIt was not until an extended-release formulation of gepirone was made available that gepirone became a potential candidate for a new antidepressant. … It represents a novel class of antidepressants that selectively targets the 5HT<sub>1A</sub> receptors, thus possessing a more favorable side effects profile with comparable incidence of sexual dysfunction
Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 1-RingExatecan
go.drugbank.com/drugs/DB12185InvestigationalExatecan has been used in trials studying the treatment of Sarcoma, Leukemia, Lymphoma, Lung Cancer, and Liver Cancer, among others.
Categories: Topoisomerase I InhibitorsObatoclax
go.drugbank.com/drugs/DB12191InvestigationalObatoclax has been used in trials studying the treatment of AML, Leukemia, Myelofibrosis, Hodgkin's Lymphoma, and Mantle-Cell Lymphoma, among others.
Categories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-Ring